Latest Clinical Trials News

Page 10 of 140
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026
Cynata Therapeutics has launched a fully underwritten $913,000 entitlement offer as it reassesses the future of its Cymerus platform after two major trials failed to demonstrate efficacy. The raise provides short-term funding, but the prospectus warns that further capital may be needed and repeats a material uncertainty over going concern.
Ada Torres
Ada Torres
8 Oct 2026
Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.
Ada Torres
Ada Torres
8 Oct 2026
Arovella Therapeutics has released a second clinical batch of its off-the-shelf CAR-iNKT therapy ALA-101, with material expected to support dose escalation and the start of dose expansion in blood cancers. The company is also adding hospital sites ahead of anticipated first-patient dosing in late October.
Ada Torres
Ada Torres
7 Oct 2026
The FDA says positive results from Neurizon’s HEALEY ALS trial could potentially support traditional approval of NUZ-001, with the study possibly serving as the sole registrational trial. The guidance is conditional, but gives the company a clearer regulatory route ahead of topline results expected in late Q2 2027.
Ada Torres
Ada Torres
6 Oct 2026
Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
Ada Torres
Ada Torres
5 Oct 2026
ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
Victor Sage
5 Oct 2026
Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.
Victor Sage
Victor Sage
5 Oct 2026
AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.
Ada Torres
Ada Torres
5 Oct 2026
CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.
Victor Sage
Victor Sage
5 Oct 2026
LTR Pharma has completed the final Phase II pharmacokinetic report for SPONTAN, confirming a median 10-minute time to peak concentration against 60 minutes for an oral vardenafil tablet. The result completes the FDA-aligned dataset ahead of planned US submission work, although efficacy in erectile dysfunction patients remains to be tested.
Victor Sage
Victor Sage
1 Oct 2026
Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026

Browse the archive

Full archive